Safety of ide-cel based on race and ethnicity
| Patient characteristics . | Hispanic n = 22 . | Non-Hispanic Black n = 36 . | Non-Hispanic White n = 149 . | P . |
|---|---|---|---|---|
| Any grade CRS, n (%) | 17 (77%) | 35 (97%) | 126 (85%) | .04 |
| CRS grade, n (%) | .3 | |||
| No CRS | 5 (23%) | 1 (3%) | 23 (15%) | |
| Grade 1 or 2 | 17 (77%) | 34 (94%) | 121 (81%) | |
| Grade ≥3 | 0 (0%) | 1 (3%) | 5 (3%) | |
| Any grade ICANS, n (%) | 4 (18%) | 6 (18%) | 29 (20%) | >.9 |
| Unknown | 1 | 3 | 7 | |
| ICANS grade, n (%) | .6 | |||
| No ICANS | 18 (82%) | 27 (82%) | 113 (80%) | |
| Grade 1 or 2 | 2 (9%) | 3 (9%) | 22 (15%) | |
| Grade ≥3 | 2 (9%) | 3 (9%) | 7 (5%) | |
| Unknown | 0 | 3 | 7 | |
| Length of hospital stay in d, median (IQR) | 8.0 (8.0-12.5) | 13.5 (8.0-17.2) | 9.0 (8.0-13.0) | .006 |
| ICU admission, n (%) | 1 (5%) | 2 (6%) | 16 (11%) | .6 |
| Hematologic toxicity, n (%) | ||||
| Grade ≥3 neutropenia at ≥30 d | 10 (59%) | 22 (71%) | 69 (57%) | .3 |
| Unknown | 5 | 5 | 27 | |
| Grade ≥3 anemia at ≥30 d | 5 (33%) | 14 (47%) | 47 (38%) | .6 |
| Unknown | 7 | 6 | 28 | |
| Grade ≥3 thrombocytopenia at ≥30 d | 8 (50%) | 19 (63%) | 71 (57%) | .7 |
| Unknown | 6 | 6 | 24 | |
| Any grade ≥3 cytopenia at ≥30 d | 12 (67%) | 29 (85%) | 90 (72%) | .2 |
| Unknown | 4 | 2 | 24 | |
| Infection, n (%) | 9 (41%) | 16 (44%) | 42 (28%) | .1 |
| Tocilizumab use, n (%) | 16 (73%) | 29 (81%) | 101 (68%) | .3 |
| Steroid use, n (%) | 5 (23%) | 11 (31%) | 42 (28%) | .8 |
| Anakinra use, n (%) | 3 (14%) | 0 (0%) | 7 (5%) | .06 |
| Patient characteristics . | Hispanic n = 22 . | Non-Hispanic Black n = 36 . | Non-Hispanic White n = 149 . | P . |
|---|---|---|---|---|
| Any grade CRS, n (%) | 17 (77%) | 35 (97%) | 126 (85%) | .04 |
| CRS grade, n (%) | .3 | |||
| No CRS | 5 (23%) | 1 (3%) | 23 (15%) | |
| Grade 1 or 2 | 17 (77%) | 34 (94%) | 121 (81%) | |
| Grade ≥3 | 0 (0%) | 1 (3%) | 5 (3%) | |
| Any grade ICANS, n (%) | 4 (18%) | 6 (18%) | 29 (20%) | >.9 |
| Unknown | 1 | 3 | 7 | |
| ICANS grade, n (%) | .6 | |||
| No ICANS | 18 (82%) | 27 (82%) | 113 (80%) | |
| Grade 1 or 2 | 2 (9%) | 3 (9%) | 22 (15%) | |
| Grade ≥3 | 2 (9%) | 3 (9%) | 7 (5%) | |
| Unknown | 0 | 3 | 7 | |
| Length of hospital stay in d, median (IQR) | 8.0 (8.0-12.5) | 13.5 (8.0-17.2) | 9.0 (8.0-13.0) | .006 |
| ICU admission, n (%) | 1 (5%) | 2 (6%) | 16 (11%) | .6 |
| Hematologic toxicity, n (%) | ||||
| Grade ≥3 neutropenia at ≥30 d | 10 (59%) | 22 (71%) | 69 (57%) | .3 |
| Unknown | 5 | 5 | 27 | |
| Grade ≥3 anemia at ≥30 d | 5 (33%) | 14 (47%) | 47 (38%) | .6 |
| Unknown | 7 | 6 | 28 | |
| Grade ≥3 thrombocytopenia at ≥30 d | 8 (50%) | 19 (63%) | 71 (57%) | .7 |
| Unknown | 6 | 6 | 24 | |
| Any grade ≥3 cytopenia at ≥30 d | 12 (67%) | 29 (85%) | 90 (72%) | .2 |
| Unknown | 4 | 2 | 24 | |
| Infection, n (%) | 9 (41%) | 16 (44%) | 42 (28%) | .1 |
| Tocilizumab use, n (%) | 16 (73%) | 29 (81%) | 101 (68%) | .3 |
| Steroid use, n (%) | 5 (23%) | 11 (31%) | 42 (28%) | .8 |
| Anakinra use, n (%) | 3 (14%) | 0 (0%) | 7 (5%) | .06 |
ICU, intensive care unit; IQR, interquartile range.